# Visualizing the Functional Dynamics of P-Glycoprotein and Its Modulation by Elacridar via High-Speed Atomic Force Microscopy

**Authors:** Yui Kanaoka, Norie Hamaguchi-Suzuki, Yuto Nonaka, Soichi Yamashita, Osamu Miyashita, Atsuyuki Ito, Satoshi Ogasawara, Florence Tama, Takeshi Murata, Takayuki Uchihashi

PMC · DOI: 10.3390/ijms27010356 · International Journal of Molecular Sciences · 2025-12-29

## TL;DR

This study uses high-speed atomic force microscopy to visualize how P-glycoprotein moves and how Elacridar affects its motion, offering new insights into drug resistance in cancer.

## Contribution

The study is the first to directly visualize the dynamic conformational changes of P-glycoprotein and how Elacridar modulates these motions.

## Key findings

- P-glycoprotein exhibits large-scale spontaneous motions in its apo state.
- Elacridar at low concentrations activates P-glycoprotein dynamics, while high concentrations rigidify it.
- High-speed atomic force microscopy reveals structural dynamics linked to drug resistance mechanisms.

## Abstract

P-glycoprotein (P-gp) is an ATP-driven transporter that effluxes a wide range of xenobiotics from cells, and its overexpression is a primary cause of multidrug resistance (MDR) in cancer. It is well-established that P-gp functions through conformational changes, yet its large-scale structural dynamics at work have been unexplored. Here, we directly visualized single P-gp molecules reconstituted in nanodiscs using high-speed atomic force microscopy (HS-AFM). The HS-AFM movies revealed that P-gp is intrinsically dynamic in its apo state, with its nucleotide-binding domains (NBDs) undergoing large, spontaneous opening and closing motions. However, addition of ATP stabilized a conformation characterized by NBD proximity with a strong tendency toward closure. We then leveraged this dynamic viewpoint to elucidate the relationship between Elacridar’s function and the resulting structural dynamics of P-gp. Elacridar is designed to overcome multidrug resistance (MDR) in cancer and acts as a potent dual inhibitor of both P-gp and the Breast Cancer Resistance Protein (BCRP), effectively blocking the drug efflux function of these transporters. This inhibitor has suggested concentration-dependent function: it is effluxed as a substrate at low concentrations and acts as an inhibitor at high concentrations. Our direct observations revealed that low concentrations induced active dynamics in P-gp, whereas high concentrations severely restricted its motion, leading to a rigid, non-productive state. Our study provides critical insights into how observing molecular motion itself can unravel complex biological mechanisms.

## Linked entities

- **Proteins:** Mdr65 (Multi drug resistance 65), PGP (phosphoglycolate phosphatase), ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group))
- **Chemicals:** Elacridar (PubChem CID 119373), ATP (PubChem CID 5957)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** ABCG2 (ATP binding cassette subfamily G member 2 (JR blood group)) [NCBI Gene 9429] {aka ABC15, ABCP, BCRP, BMDP, CD338, CDw338}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}
- **Diseases:** cancer (MESH:D009369), MDR (MESH:D018088)
- **Chemicals:** ATP (MESH:D000255), nucleotide (MESH:D009711), Elacridar (MESH:C083501)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12785683/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12785683/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12785683/full.md

---
Source: https://tomesphere.com/paper/PMC12785683